Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Recruiting
Observational Study
Primary Biliary Cirrhosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- University of Aarhus · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* PBC patient offered bezafibrate treatment
Exclusion Criteria:
* patient age under 18
* life expectancy less than 6 months
* known cancer
* planned liver transplantation within 6 months
* other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)
Contacts